Page last updated: 2024-09-03

vadimezan and Angiogenesis, Pathologic

vadimezan has been researched along with Angiogenesis, Pathologic in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (7.14)	18.2507
2000's	20 (47.62)	29.6817
2010's	18 (42.86)	24.3611
2020's	1 (2.38)	2.80

Authors

Authors	Studies
Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA	1
Cichoń, T; Jarosz-Biej, M; Kułach, N; Pilny, E; Poczkaj, A; Smolarczyk, R; Szala, S	1
Banciu, M; Bulzu, P; Licarete, E; Luput, L; Patras, L; Rakosy-Tican, E; Rauca, VF; Sesarman, A	1
Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R	1
Aghaei, M; Downey, CM; Jirik, FR; Schwendener, RA	1
Cao, N; Du, G; Duan, Y; Guo, Z; Han, G; Li, G; Li, H; Lin, H; Liu, L; Ma, X	1
Gevertz, JL	1
Rehman, F; Rustin, G	1
Bellnier, DA; Cheney, RT; Seshadri, M	1
Ciesielski, MJ; Seshadri, M	1
Head, M; Jameson, MB	1
Brauer, R; Bridewell, DJ; Ching, LM; Henare, K; Kieda, C; Malinger, D; Palmer, BD; Tijono, SM; Vogel, SN; Wang, LC; Woon, ST	1
Baguley, BC; McKeage, MJ	1
Cai, YC; Xian, LJ; Zou, Y	1
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM	1
de Witte, P; Lerut, E; Marysael, T; Ni, Y	1
Coulthard, T; Sacadura, NT; Seshadri, M	1
Azabdaftari, G; Ellis, L; Hammers, H; Lehet, K; Pili, R; Seshadri, M; Shah, P; Sotomayor, P	1
Hu, Y; Li, Y; Lou, L; Quan, H; Wu, Q; Xu, Y	1
Kim, S; Mitchison, TJ; Peshkin, L	1
Gehmert, S; Geissler, EK; Hackl, C; Jung, EM; Lang, SA; Moser, C; Pfister, K; Schlitt, HJ; Schnitzbauer, AA; Stroszczynski, C	1
Baguley, BC; Wilson, WR	1
Baguley, BC; Ching, LM	1
Horsman, MR; Murata, R	1
Horsman, MR; Siemann, DW	1
Baguley, BC; Ching, LM; Kelland, LR; Kestell, P; Zhao, L	1
Chung, YL; Clark, S; Griffiths, JR; Kelland, LR; Madhu, B; McPhail, LD; Robinson, SP	1
Baguley, BC; Kanthou, C; Tozer, GM	1
Bellnier, DA; Camacho, SH; Cheney, RT; Mazurchuk, R; Oseroff, AR; Seshadri, M; Spernyak, JA	1
Raben, D; Ryan, A	1
Albelda, SM; Burdick, MD; Cheung, L; Ching, LM; Jassar, AS; Kaiser, LR; Kapoor, V; Silverberg, MB; Strieter, RM; Sun, J; Suzuki, E	1
Griffiths, JR; Kelland, LR; Kestell, P; Ludwig, C; McIntyre, DJ; McPhail, LD; Robinson, SP	1
Chaplin, DJ; Horsman, MR; Siemann, DW	1
Bellnier, DA; Bhattacharya, A; Mazurchuk, R; Rustum, YM; Seshadri, M; Spernyak, JA	1
Eskens, FA; Hinnen, P	1
Griffiths, JR; McPhail, LD; Robinson, SP	1
Holford, NH; Pruijn, FB; van Daalen, M; Wilson, WR	1
Baguley, BC; Ching, LM; Goldsmith, D; Joseph, WR; Körner, H; Sedgwick, JD	1
Begent, RH; Boden, R; Boxer, GM; Davies, L; Pedley, RB; Sharma, SK; Springer, CJ; Stribbling, SM	1
Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S	1
Lepler, S; Mercer, E; Rojiani, AM; Siemann, DW	1

Reviews

9 review(s) available for vadimezan and Angiogenesis, Pathologic

Article	Year
ASA404: update on drug development. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Design; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones	2008
ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future oncology (London, England), 2010, Volume: 6, Issue:10 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones	2010
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones	2010
Potential of DMXAA combination therapy for solid tumors. Expert review of anticancer therapy, 2002, Volume: 2, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Genetic Therapy; Humans; Neoplasms; Neovascularization, Pathologic; Xanthenes; Xanthones	2002
Enhancement of radiation therapy by vascular targeting agents. Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Xanthenes; Xanthones	2002
Disrupting tumour blood vessels. Nature reviews. Cancer, 2005, Volume: 5, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Capillary Permeability; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Xanthones	2005
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Vascular Endothelial Growth Factors; Xanthones	2005
Current development status of small-molecule vascular disrupting agents. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones	2006
Vascular disrupting agents in clinical development. British journal of cancer, 2007, Apr-23, Volume: 96, Issue:8 Topics: Animals; Antineoplastic Agents; Blood Vessels; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones	2007

Other Studies

33 other study(ies) available for vadimezan and Angiogenesis, Pathologic

Article	Year
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression. Scientific reports, 2021, 11-11, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones	2021
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors. Scientific reports, 2018, 05-09, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digoxin; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Melanoma; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Xanthones; Xenograft Model Antitumor Assays	2018
Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells. PloS one, 2018, Volume: 13, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Cell Communication; Cell Movement; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Macrophages; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Simvastatin; Tumor Microenvironment; Xanthones	2018
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3 Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones	2014
DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PloS one, 2014, Volume: 9, Issue:6 Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Cell Polarity; Clodronic Acid; Humans; Inflammation; Liposomes; Lung Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Transgenic; Necrosis; Neovascularization, Pathologic; Nucleotides, Cyclic; Phenotype; ras Proteins; Subcutaneous Tissue; Tumor Suppressor Protein p53; Xanthones; Xenograft Model Antitumor Assays	2014
Tumor interstitial fluid promotes malignant phenotypes of lung cancer independently of angiogenesis. Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:11 Topics: Animals; Apoptosis; Aquaporin 1; Autophagy; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Fluid; Female; Humans; Hydroxyindoleacetic Acid; Inflammation; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Wound Healing; Xanthones	2015
Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs. Advances in experimental medicine and biology, 2016, Volume: 936 Topics: Angiogenesis Inhibitors; Bevacizumab; Bibenzyls; Computer Simulation; Cytotoxins; Drug Combinations; Drug Dosage Calculations; Endothelial Cells; Everolimus; Humans; Models, Statistical; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xanthones	2016
Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors. International journal of radiation oncology, biology, physics, 2008, Nov-15, Volume: 72, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Female; Fibrosarcoma; Image Enhancement; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Treatment Outcome; Xanthones	2008
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2009, Volume: 29, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cerebral Angiography; Contrast Media; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Treatment Outcome; Xanthones; Xenograft Model Antitumor Assays	2009
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Neoplasms; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Xanthones	2010
Novel agents target existing tumor vasculature. Expert review of anticancer therapy, 2010, Volume: 10, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Neovascularization, Pathologic; Xanthones	2010
Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:9 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cells, Cultured; Electrophoresis, Gel, Two-Dimensional; Endothelial Cells; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidation-Reduction; Photoaffinity Labels; Photochemistry; Proteins; RNA, Small Interfering; Signal Transduction; Spleen; Staining and Labeling; Xanthones	2010
Cardiovascular toxicity profiles of vascular-disrupting agents. The oncologist, 2011, Volume: 16, Issue:8 Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones	2011
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:11 Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Perylene; Telomere-Binding Proteins; Xanthones	2011
Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging. Angiogenesis, 2011, Volume: 14, Issue:4 Topics: Animals; Area Under Curve; Carcinoma, Squamous Cell; Female; Gadolinium; Head and Neck Neoplasms; Humans; Magnetic Resonance Angiography; Mice; Mice, Nude; Neovascularization, Pathologic; Organometallic Compounds; Transplantation, Heterologous; Ultrasonography; Xanthones	2011
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular cancer therapeutics, 2012, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antigens; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Sirolimus; Spheroids, Cellular; TOR Serine-Threonine Kinases; Tumor Burden; Xanthones; Xenograft Model Antitumor Assays	2012
p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:3 Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Lewis Lung; Female; Human Umbilical Vein Endothelial Cells; Humans; Injections, Intraperitoneal; Macrophages; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; RNA Interference; Tumor Necrosis Factor-alpha; Xanthones	2012
Vascular disrupting agent drug classes differ in effects on the cytoskeleton. PloS one, 2012, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Capillary Permeability; Cell Line; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Mice; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Stilbenes; Xanthones	2012
Contrast-enhanced ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer. Clinical hemorheology and microcirculation, 2014, Volume: 56, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Random Allocation; Stomach Neoplasms; Ultrasonography, Interventional; Xanthones; Xenograft Model Antitumor Assays	2014
DMXAA: an antivascular agent with multiple host responses. International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Models, Chemical; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitric Oxide; Receptors, Tumor Necrosis Factor; Serotonin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones	2002
Combination of vascular targeting agents with thermal or radiation therapy. International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones	2002
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. International journal of cancer, 2005, Aug-20, Volume: 116, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Capillary Permeability; Colonic Neoplasms; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Receptors, Tumor Necrosis Factor, Type I; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthones	2005
Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-15, Volume: 11, Issue:10 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Membrane; Colonic Neoplasms; Dose-Response Relationship, Drug; Energy Metabolism; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Transplantation, Heterologous; Xanthones	2005
Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11 Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Capillary Permeability; Chlorophyll; Combined Modality Therapy; Dose-Response Relationship, Drug; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Photochemotherapy; Platelet Endothelial Cell Adhesion Molecule-1; Treatment Outcome; Xanthones	2005
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer research, 2005, Dec-15, Volume: 65, Issue:24 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokines; Cytokines; Disease Models, Animal; Immunotherapy; Lung Neoplasms; Macrophages; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neovascularization, Pathologic; Perforin; Pore Forming Cytotoxic Proteins; Xanthones	2005
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia (New York, N.Y.), 2006, Volume: 8, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Biomarkers; Capillary Permeability; Cell Line, Tumor; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactinoma; Rats; Rats, Inbred WF; Subcutaneous Tissue; Xanthones	2006
Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia (New York, N.Y.), 2006, Volume: 8, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Xanthones	2006
Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. International journal of radiation oncology, biology, physics, 2007, Nov-15, Volume: 69, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Female; Hemoglobins; Magnetic Resonance Imaging; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Inbred WF; Stilbenes; Xanthones	2007
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:6 Topics: Animals; Antineoplastic Agents, Alkylating; Cell Hypoxia; Drug Synergism; Female; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Xanthenes; Xanthones	1997
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer research, 1999, Jul-15, Volume: 59, Issue:14 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Hemorrhage; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Proteins; Neovascularization, Pathologic; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones	1999
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer research, 1999, Aug-15, Volume: 59, Issue:16 Topics: Animals; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; gamma-Glutamyl Hydrolase; Glutamates; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrogen Mustard Compounds; Prodrugs; Transplantation, Heterologous; Xanthenes; Xanthones	1999
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer research, 2001, Mar-01, Volume: 61, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Flavonoids; Gene Dosage; Genetic Therapy; Genetic Vectors; Immunotherapy; Killer Cells, Natural; Lymphocyte Subsets; Lymphoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; Thymus Neoplasms; Xanthenes; Xanthones	2001
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. International journal of cancer, 2002, May-01, Volume: 99, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Necrosis; Neovascularization, Pathologic; Sarcoma, Experimental; Stilbenes; Tumor Cells, Cultured; Xanthenes; Xanthones	2002